232 related articles for article (PubMed ID: 17633803)
1. [The bacillus Calmette-Guérin as immunomodulator in bladder cancer].
Vázquez-Lavista LG; Flores-Balcázar CH; Llorente L
Rev Invest Clin; 2007; 59(2):146-52. PubMed ID: 17633803
[TBL] [Abstract][Full Text] [Related]
2. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
3. Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
Böhle A; Busemann E; Gerdes J; Ulmer AJ; Flad HD; Jocham D
Dev Biol Stand; 1992; 77():199-209. PubMed ID: 1426663
[TBL] [Abstract][Full Text] [Related]
4. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy.
Ozbakkaloglu B; Tünger O; Sürücüoglu S; Lekili M; Kandiloglu AR
Int Urol Nephrol; 1999; 31(1):49-53. PubMed ID: 10408303
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
6. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
8. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
10. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder.
Rosevear HM; Lightfoot AJ; O'Donnell MA; Griffith TS
Cancer Metastasis Rev; 2009 Dec; 28(3-4):345-53. PubMed ID: 19967427
[TBL] [Abstract][Full Text] [Related]
11. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
12. Intracavitary bacillus Calmette-Guérin for Superficial Bladder Tumors.
Droller MJ
J Urol; 2017 Feb; 197(2S):S146-S147. PubMed ID: 28010983
[No Abstract] [Full Text] [Related]
13. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
[TBL] [Abstract][Full Text] [Related]
14. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
15. Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer.
Danişman A; Bulut K; Kukul E; Ozen I; Sevük M
Urol Int; 2000; 64(4):198-201. PubMed ID: 10895085
[TBL] [Abstract][Full Text] [Related]
16. [Granulomatous prostatitis as collateral effect of intravesical immunotherapy with BCG].
Mattei FM; Giovannelli V; Schepis L; Del Vecchio MT; Di Renzo M
Arch Ital Urol Androl; 1998 Sep; 70(4):177-82. PubMed ID: 9823665
[TBL] [Abstract][Full Text] [Related]
17. Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro.
Schneider B; Thanhäuser A; Jocham D; Loppnow H; Vollmer E; Galle J; Flad HD; Ulmer AJ; Böhle A
World J Urol; 1994; 12(6):337-44. PubMed ID: 7881473
[TBL] [Abstract][Full Text] [Related]
18. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
[TBL] [Abstract][Full Text] [Related]
19. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
[TBL] [Abstract][Full Text] [Related]
20. Small bladder and multiple urethral recurrences after intravesical instillation of bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
Manasia P; Alcaraz A; Cetina A; Alcover J
J Urol; 2001 Feb; 165(2):529-30. PubMed ID: 11176420
[No Abstract] [Full Text] [Related]
[Next] [New Search]